Pieris Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Stock and Employee Benefit Plans (Tables)

12 Months Ended

Dec. 31, 2016

A summary of the status of the Company’s 2014 plan as of December 31, 2016 and changes during the year then ended is as follows:


	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life		Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2015		2,707,329		$	2.05		9.17 years	$	741
Granted		1,157,734			1.57
Forfeited		(140,000	)		1.71

Outstanding, December 31, 2016		3,725,063		$	1.91		8.55 years	$	—

Vested or expected to vest		3,725,063		$	1.91		8.55 years	$	—

Exercisable, December 31, 2016		1,961,811		$	2.01		7.99 years	$	—

A summary of the status of the Company’s 2016 plan as of December 31, 2016 and changes during the year then ended is as follows:


	Number of Options		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life		Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2015		—	$	—		—	$	—
Granted		715,313		2.36

Outstanding, December 31, 2016		715,313	$	2.36		9.62 years	$	—

Vested or expected to vest		715,313	$	2.36		9.62 years	$	—

Exercisable, December 31, 2016		228,774	$	2.46		8.90 years	$	—